Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "AMU"

113 News Found

Lupin enters Guinness Records highlights rise in strokes
Public Health | October 25, 2021

Lupin enters Guinness Records highlights rise in strokes

This unique record was made possible by collating hard copies of the books in a structured manner


Lancet Respiratory Medicine publishes Phase 2 data of Medigen Covid-19 vaccine
News | October 16, 2021

Lancet Respiratory Medicine publishes Phase 2 data of Medigen Covid-19 vaccine

The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres


Astra’s antibody injection trial indicates it can prevent and treat Covid-19
Biotech | October 11, 2021

Astra’s antibody injection trial indicates it can prevent and treat Covid-19

AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial


Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


Indian Railways to deploy HMIS across its network
Digitisation | September 04, 2021

Indian Railways to deploy HMIS across its network

Implementation of the system to provide faster, seamless and hassle-free healthcare solutions


Mindpeers launches on-demand behavioural healthcare platform
Healthcare | August 04, 2021

Mindpeers launches on-demand behavioural healthcare platform

It is designed to tackle mental health issues


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Gap between two doses of Covishield extended; No extension for Covaxin
News | May 14, 2021

Gap between two doses of Covishield extended; No extension for Covaxin

The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield


COVAXIN phase II/III clinical trial approved for 2-18 years
News | May 13, 2021

COVAXIN phase II/III clinical trial approved for 2-18 years

BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years